Apatinib Inhibits Tumor Growth and Angiogenesis in PNET Models


Introduction: Angiogenesis has a pivotal role in the growth and metastasis of pancreatic neuroendocrine tumors (PNETs). Apatinib inhibits angiogenesis as a highly selective KDR inhibitor and has been used to treat advanced gastric cancer and malignancies in clinical settings. However, the efficacy of apatinib in PNETs remains unclear.

Aim(s): The present study aims to compare the antitumor efficacy of apatinib with that of the standard PNET drug sunitinib in our subcutaneous and liver metastasis models of insulinoma and non-functional PNET.

Materials and methods: The antitumor potential of apatinib was evaluated in INR1G9-represented non-functional PNET and INS-1-represented insulinoma subcutaneous xenograft models and liver metastasis models. Tumor volume, angiogenesis and hypoxic area formation were analyzed. Cytotoxicity of apatinib on tumor cells was measured by using CCK-8 in vitro.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Wang z

Authors: Wu S, Zhou J, Guo J, Hua Z, Li J,

Keywords: Pancreatic neuroendocrine tumors, angiogenesis, KDR, apatinib, liver metastasis,

To read the full abstract, please log into your ENETS Member account.